LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,619
تعداد دریافت فایل اصل مقاله11,291,420
Javan-Noughabi, Javad, Mousavi, Sayed Ali, Hashemi, Seyed Yaser, Faramarzi, Ahmad, Bahrami Asl, Farshad, Shabanikiya, Hamidreza. (1401). Epidemiological Indices of COVID-19 Viruses in Countries with High-incidence: A Descriptive and Comparative Analysis. سامانه مدیریت نشریات علمی, 11(1 (Supplement)), 164-169. doi: 10.30476/jhsss.2021.92408.1347
Javad Javan-Noughabi; Sayed Ali Mousavi; Seyed Yaser Hashemi; Ahmad Faramarzi; Farshad Bahrami Asl; Hamidreza Shabanikiya. "Epidemiological Indices of COVID-19 Viruses in Countries with High-incidence: A Descriptive and Comparative Analysis". سامانه مدیریت نشریات علمی, 11, 1 (Supplement), 1401, 164-169. doi: 10.30476/jhsss.2021.92408.1347
Javan-Noughabi, Javad, Mousavi, Sayed Ali, Hashemi, Seyed Yaser, Faramarzi, Ahmad, Bahrami Asl, Farshad, Shabanikiya, Hamidreza. (1401). 'Epidemiological Indices of COVID-19 Viruses in Countries with High-incidence: A Descriptive and Comparative Analysis', سامانه مدیریت نشریات علمی, 11(1 (Supplement)), pp. 164-169. doi: 10.30476/jhsss.2021.92408.1347
Javan-Noughabi, Javad, Mousavi, Sayed Ali, Hashemi, Seyed Yaser, Faramarzi, Ahmad, Bahrami Asl, Farshad, Shabanikiya, Hamidreza. Epidemiological Indices of COVID-19 Viruses in Countries with High-incidence: A Descriptive and Comparative Analysis. سامانه مدیریت نشریات علمی, 1401; 11(1 (Supplement)): 164-169. doi: 10.30476/jhsss.2021.92408.1347

Epidemiological Indices of COVID-19 Viruses in Countries with High-incidence: A Descriptive and Comparative Analysis

Journal of Health Sciences & Surveillance System
دوره 11، 1 (Supplement)، فروردین 2023، صفحه 164-169    اصل مقاله (286.61 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.30476/jhsss.2021.92408.1347
نویسندگان
Javad Javan-Noughabi1؛ Sayed Ali Mousavi2؛ Seyed Yaser Hashemi3؛ Ahmad Faramarzi* 4؛ Farshad Bahrami Asl5؛ Hamidreza Shabanikiya6
1Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2Department of Health, Shoushtar Faculty of Medical Science, Shoushtar, Iran
3Fasa University of Medical Sciences, Fasa, Iran
4Department of Health Management and Economics, School of Public Health, Urmia University of Medical Sciences, Urmia, Iran
5Department of Environmental Health Engineering, School of Health, Urmia University of Medical Sciences, Urmia, Iran
6Department of Health Economics and Management Sciences, Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Background: Coronavirus disease 2019 (COVID-19) has posed an unusual threat to global health. Up to May 26, 2021, according to a report by the World Health Organization (WHO), 167.01 million cases, and 3.47 million deaths were reported. This study aimed to estimate and compare epidemiological indices of COVID-19 in high-incidence countries.
Methods: We conducted a descriptive and comparative analysis intending to examine the epidemiological indices of COVID- 19 in high-incidence countries, using the data published by the WHO until May 17, 2021. We calculated the incidence and mortality rate per 1,000,000 inhabitant-day at risk daily, weekly, and overall, using person-day as the denominator.
Results: The fatality rate in 14 countries was about 1.94%. The highest fatality rate was acquired in Italy (2.99%), followed by the United Kingdom (2.86%) and Iran (2.79%). The lowest value on the fatality rate was in Turkey and India, at 0.88% and 1.1%. The highest incidence rate was reported in the USA (207 cases per 1,000,000 person-day), followed by France (190), Poland (171), and Argentina (167). The highest mortality rate for the whole period was extracted in Brazil (4.60 death per 1,000,000 population-day), and the lowest rate happened in India (0.42).
Conclusion: Until May 17, 2021, COVID-19 has affected about 117.6 million patients and caused 2.3 million deaths in 14 highincidence countries. This study shows that a specific pattern of COVID-19 has been observed in every country.
کلیدواژه‌ها
COVID-19؛ Fatality؛ Incidence؛ Mortality
مراجع
  1. ul Qamar MT, Alqahtani SM, Alamri MA, Chen L-L. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10(4):313-9. doi: 10.1016/j.jpha.2020.03.009. PMID: 32296570.
  2. Ornell F, Schuch JB, Sordi AO, Kessler FHP. “Pandemic fear” and COVID-19: mental health burden and strategies. Braz J Psychiatry. 2020;42(3):232-5. doi: 10.1590/1516-4446-2020-0008. PMID: 32267343.
  3. Kandel N, Chungong S, Omaar A, Xing J. Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. The Lancet. 2020;395(10229):1047-53. doi: 10.1016/S0140-6736(20)30553-5. PMID: 32199075.
  4. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23(8):468-78. doi: 10.1016/j.tim.2015.06.003. PMID: 26206723.
  5. Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26(5):483-95. doi: 10.1016/j.molmed.2020.02.008. PMID: 32359479.
  6. Lai C-C, Wang C-Y, Wang Y-H, Hsueh S-C, Ko W-C, Hsueh P-R. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946. doi: 10.1016/j.ijantimicag.2020.105946. PMID: 32199877.
  7. Chih-Cheng L, Cheng-Yi W, Ya-Hui W, Shun-Chung H, Wen-Chien K, Po-Ren H. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55. doi: 10.1016/j.ijantimicag.2020.105946. PMID: 32199877.
  8. Rodriguez-Villamizar LA, Belalcázar-Ceron LC, Fernández-Niño JA, Marín-Pineda DM, Rojas-Sánchez OA, Acuña-Merchán LA, et al. Air pollution, sociodemographic and health conditions effects on COVID-19 mortality in Colombia: an ecological study. Sci Total Environ. 2021;756:144020. doi: 10.1016/j.scitotenv.2020.144020. PMID: 33279185.
  9. Wildman J. COVID-19 and income inequality in OECD countries. Eur J Health Econ. 2021;22(3):455-62. doi: 10.1007/s10198-021-01266-4. PMID: 33590424.
  10. Mokhtari AM, Susan Dewey R, Mirahmadizadeh A. The Global Challenges of Controlling Coronavirus Disease 2019: A Review Study. Journal of Health Sciences & Surveillance System. 2021;9(3):142-8. doi: 10.30476/jhsss.2021.90136.1179.
  11. Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: ethical issues. Lancet Infect Dis. 2020;20(8):e198-e203. doi: 10.1016/S1473-3099(20)30438-2. PMID: 32479747.
  12. Coronavirus Disease (COVID-19) Dashboard. 2021. Available from: https://covid19.who.int/table.
  13. Baldwin R, Weder di Mauro B. Economics in the Time of COVID-19. CEPR Press; 2020.
  14. Kharas H, Hamel K. IMF’s World Economic Outlook, Initial Assessment of a country-by-country of what might happen to the world economy in 2020 and 2021. IMF; 2020.
  15. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020:105955. doi: 10.1016/j.ijantimicag.2020.105955. PMID: 32234468.
  16. Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23(4):268-71. doi: 10.34172/aim.2020.09. PMID: 32271601.
  17. Roosa K, Lee Y, Luo R, Kirpich A, Rothenberg R, Hyman J, et al. Real-time forecasts of the COVID-19 epidemic in China from February 5 to February 24, 2020. Infect Dis Model. 2020;5:256-63. doi: 10.1016/j.idm.2020.02.002.
  18. United Nations. World Population Prospects 2019. 2020. Available from: http://creativecommons.org/licenses/by/3.0/igo/.
  19. Li Lq, Huang T, Wang Yq, Wang Zp, Liang Y, Huang Tb, et al. COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis. J Med Virol. 2020;92(6):577-83. doi: 10.1002/jmv.25757. PMID: 32162702.
  20. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: discovery, diagnostics and drug development. J Hepatol. 2020. doi: 10.1016/j.jhep.2020.09.031. PMID: 33038433.
  21. Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Hanses F. [Epidemiology of SARS-CoV-2 infection and COVID-19]. Internist (Berl). 2020;61(8):782-8. doi: 10.1007/s00108-020-00834-9. PMID: 32548652.
  22. He W, Yi GY, Zhu Y. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID‐19: Meta‐analysis and sensitivity analysis. J Med Virol. 2020;92(11):2543-50. doi: 10.1002/jmv.26041. PMID: 32470164.
  23. Cao Y, Hiyoshi A, Montgomery S. COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data. BMJ open. 2020;10(11):e043560. doi: 10.1136/bmjopen-2020-043560. PMID: 33148769.
  24. Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020;24(23):12593-608. doi: 10.26355/eurrev_202012_24057. PMID: 33336780.
  25. Buja A, Paganini M, Cocchio S, Scioni M, Rebba V, Baldo V. Demographic and socio-economic factors, and healthcare resource indicators associated with the rapid spread of COVID-19 in Northern Italy: An ecological study. PLoS One. 2020;15(12):e0244535. doi: 10.1371/journal.pone.0244535. PMID: 33370383.
  26. Shahrajabian MH, Sun W, Cheng Q. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Hum Vaccin Immunother. 2020:1-22. doi: 10.1080/21645515.2020.1797369. PMID: 32783700.
  27. Update 49 - SARS case fatality ratio, incubation period. 2003. Available from: https://www.who.int/csr/sars/ archive/2003_05_07a/en/.
  28. Donnelly C, Malik M, Elkholy A, Cauchemez S, Van Kerkhove M. Important reductions in the global number of MERS cases and deaths since 2016. Emerg Infect Dis. 2019;25(9). doi: 10.3201/eid2509.190143. PMID: 31264567.
  29. Lai C-C, Wang C-Y, Wang Y-H, Hsueh P-R. Global coronavirus disease 2019: What has daily cumulative index taught us? Int J Antimicrob Agents. 2020;55(6):106001. doi: 10.1016/j.ijantimicag.2020.106001. PMID: 32360230.
آمار
تعداد مشاهده مقاله: 377
تعداد دریافت فایل اصل مقاله: 247


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب